2018
A Phase I Dose‐Escalation Study of Clofarabine in Patients with Relapsed or Refractory Low‐Grade or Intermediate‐Grade B‐Cell or T‐Cell Lymphoma
Foss FM, Parker T. A Phase I Dose‐Escalation Study of Clofarabine in Patients with Relapsed or Refractory Low‐Grade or Intermediate‐Grade B‐Cell or T‐Cell Lymphoma. The Oncologist 2018, 23: 397-e30. PMID: 29438091, PMCID: PMC5896711, DOI: 10.1634/theoncologist.2017-0658.Peer-Reviewed Original ResearchConceptsCutaneous T-cell lymphomaT-cell lymphomaNon-Hodgkin lymphomaOverall response rateIntermediate-grade B-cellB cellsPartial responseResponse ratePhase I dose-escalation studyRefractory acute lymphoblastic leukemiaI dose-escalation studyT-cell non-Hodgkin lymphomaB-cell non-Hodgkin lymphomaPositron emission tomography scanSecond-generation purine nucleoside analogAggressive B-cell lymphomasPhase IDose of clofarabineGrade 3 leukopeniaLow-dose cohortMinimal hematologic toxicityRefractory acute leukemiaRefractory low gradeRefractory lymphoid malignanciesSingle-agent rituximab
2015
Management of isolated calf vein thrombosis in cancer patients
Brahmandam AS, Brownson K, Skrip L, Parker T, Indes J, Sarac T, Dardik A, Chaar CI. Management of isolated calf vein thrombosis in cancer patients. Vascular 2015, 24: 64-69. PMID: 25957344, DOI: 10.1177/1708538115584726.Peer-Reviewed Original ResearchConceptsCalf vein thrombosisIsolated calf vein thrombosisVein thrombosisHistory of cancerCancer patientsBenefits of anticoagulationInitiation of anticoagulationPatient risk factorsRetrospective chart reviewLong-term recurrenceChart reviewConsecutive patientsTreatment modalitiesRisk factorsThrombosisHigh incidencePatientsAnticoagulationOlder ageCancerMortalityIncidenceAnatomical characteristicsTreatmentRecurrence